CRISPR Therapeutics CRSP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.1M+16.9% | $3.51M-90.8% | $38.34M+0.8% | $38.05M+1.0% | $37.68M+1.0% | ||
| $280.9M-1.4% | $284.81M+4.3% | $273.02M-7.9% | $296.28M-3.4% | $306.55M-1.2% | ||
| $71.43M-2.9% | $73.54M+0.4% | $73.27M-0.7% | $73.76M-0.8% | $74.32M+1.8% | ||
| $650.5M-2.6% | $668.08M+9.0% | $612.73M+3.8% | $590.52M+15.3% | $512.08M+1.6% | ||
| -$646.4M+2.7% | -$664.57M-15.7% | -$574.4M-4.0% | -$552.47M-16.5% | -$474.4M-1.7% | ||
| -15,754.2%+3,179pp | -18,933.6%-17,435pp | -1,498.3%-46.3pp | -1,451.9%-193pp | -1,259.2%-8.8pp | ||
| $81.23M-6.2% | $86.61M-3.6% | $89.82M+1.3% | $88.65M-4.4% | $92.72M-10.8% | ||
| -$565.17M+2.2% | -$577.97M-19.3% | -$484.58M-4.5% | -$463.82M-21.5% | -$381.69M-5.2% | ||
| $3.36M-7.4% | $3.63M-2.3% | $3.72M-6.5% | $3.98M+0.1% | $3.97M+10.7% | ||
| -$568.53M+2.2% | -$581.6M-19.1% | -$488.3M-4.4% | -$467.8M-21.3% | -$385.66M-5.3% | ||
| -13,856.5%+2,713pp | -16,569.8%-15,296pp | -1,273.7%-44.3pp | -1,229.4%-206pp | -1,023.6%-42.1pp | ||
| -$6.20+4.6% | -$6.50-16.7% | -$5.57-3.0% | -$5.41-20.2% | -$4.50-3.4% | ||
| -$627.33M+2.8% | -$645.09M-16.1% | -$555.74M-4.2% | -$533.5M-17.2% | -$455.24M-1.8% | ||
| -15,289.6%+3,089pp | -18,378.7%-16,929pp | -1,449.6%-47.5pp | -1,402.1%-194pp | -1,208.3%-9.6pp | ||
| -$646.4M+2.7% | -$664.57M-15.7% | -$574.4M-4.0% | -$552.47M-16.5% | -$474.4M-1.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CRISPR Therapeutics's income statement data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.